`Date Filed: Aug. 19, 2016
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`________________
`
`AMERIGEN PHARMACEUTICALS LIMITED
`Petitioner,
`
`v.
`
`JANSSEN ONCOLOGY, INC.,
`Patent Owner.
`
`________________
`
`Case IPR2016-00286
`Patent 8,822,438 B2
`
`________________
`
`
`JANSSEN ONCOLOGY, INC.’S MOTION FOR PRO HAC VICE
`ADMISSION OF S. ISAAC OLSON
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2016-00286
`Patent No. 8,822,438 B2
`
`
`
`Pursuant to 37 C.F.R. § 42.10(c) and the Board’s December 10, 2015 Notice
`
`of Filing Date Accorded to Petition and Time for Filing Patent Owner Preliminary
`
`Response (Paper 4), Patent Owner Janssen Oncology, Inc. (“Janssen”) respectfully
`
`requests the pro hac vice admission of attorney S. Isaac Olson in this proceeding.
`
`Patent Owner has conferred with counsel for Amerigen Pharmaceuticals Limited
`
`(“Petitioner”), and Petitioner does not oppose this motion.
`
`I.
`
`Statement of Facts Showing Good Cause for the Board to Recognize S.
`Isaac Olson Pro Hac Vice in this Proceeding
`
`The Board may recognize counsel pro hac vice during an inter partes review
`
`proceeding upon a showing of good cause, “subject to the condition that lead
`
`counsel be a registered practitioner and to any other conditions as the Board may
`
`impose.” 37 C.F.R. § 42.10(c). For example, “where the lead counsel is a
`
`registered practitioner, a motion to appear pro hac vice by counsel who is not a
`
`registered practitioner may be granted upon showing that counsel is an experienced
`
`litigating attorney and has an established familiarity with the subject matter at issue
`
`in the proceeding.” Id.
`
`As set forth below and in the accompanying Declaration of S. Isaac Olson in
`
`Support of Motion to Appear Pro Hac Vice (“Olson Decl.,” Exhibit 2027), the facts
`
`here establish good cause for the Board to recognize S. Isaac Olson pro hac vice in
`
`this proceeding.
`
`
`
`2
`
`
`
`IPR2016-00286
`Patent No. 8,822,438 B2
`
`1. Lead Counsel, Dianne Elderkin, is a registered practitioner (Reg. No.
`
`28,598).
`
`2. Mr. Olson is a member in good standing of the State Bar of New York
`
`(Bar No. 4625190). See Exhibit 2027, ¶ 2.
`
`3. Mr. Olson has never been suspended or disbarred from practice before
`
`any court or administrative body. See Exhibit 2027, ¶ 3.
`
`4. None of Mr. Olson’s applications for admission to practice before any
`
`court or administrative body have ever been denied. See Exhibit 2027, ¶ 4.
`
`5. Mr. Olson has not been sanctioned nor has he had a contempt citation
`
`imposed on him by any court or administrative body. See Exhibit 2027, ¶ 5.
`
`6. Mr. Olson has declared that he has read and will comply with the
`
`Office Patent Trial Practice Guide and the Board’s Rules of Practice for Trial set
`
`forth in part 42 of 37 C.F.R. See Exhibit 2027, ¶ 6.
`
`7. Mr. Olson has acknowledged and agrees that he will be subject to the
`
`USPTO Rules of Professional Conduct set forth in 37 C.F.R. § 11.101 et. seq. and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a). See Exhibit 2027, ¶ 7.
`
`8. Mr. Olson has not applied to appear pro hac vice before the Patent
`
`Trial and Appeal Board in the last three years. See Exhibit 2027, ¶ 8.
`
`9. Mr. Olson has been a practicing attorney for almost 9 years and has
`
`been involved in numerous patent cases. He is presently counsel for Janssen in
`
`
`
`3
`
`
`
`IPR2016-00286
`Patent No. 8,822,438 B2
`
`pending patent litigations involving the patent under review in this proceeding,
`
`U.S. Patent No. 8,822,438 (the “’438 patent”). These cases are captioned BTG
`
`Int’l Ltd., et al. v. Actavis Labs. FL, Inc., et al., C.A. No. 2:15-cv-05909-KM-JBC
`
`(D.N.J.) and Janssen Biotech, Inc., et al. v. Mylan Pharm. Inc., et al., C.A. No.
`
`1:15-cv-00130-IMK (N.D. W. Va.). As part of these litigations, Mr. Olson has
`
`studied and analyzed the ’438 patent and has become very familiar with its subject
`
`matter. He is also familiar with prior art asserted in this IPR proceeding,
`
`conception and reduction to practice of the inventions claimed in the ’438 patent,
`
`and claim construction of various claim terms. See Exhibit 2027, ¶ 9.
`
`In view of Mr. Olson’s knowledge of the subject matter at issue in this
`
`proceeding, and in view of the interrelatedness of this proceeding and the two
`
`district court litigations mentioned above, Janssen has a substantial need for Mr.
`
`Olson’s pro hac vice admission and his involvement in the continued prosecution
`
`of this proceeding. In addition, pro hac vice admission of Mr. Olson will enable
`
`Janssen to avoid unnecessary expense and duplication of work between this
`
`proceeding and the related district court litigations. See 77 Fed. Reg. 48,612,
`
`48,661 (Aug. 14, 2012) (Office’s comment on final rule discussing concerns about
`
`efficiency and costs where an entity has already engaged counsel for parallel
`
`district court litigation).
`
`
`
`
`
`
`
`4
`
`
`
`IPR2016-00286
`Patent No. 8,822,438 B2
`
`II.
`
`Conclusion
`
`For the foregoing reasons, Patent Owner Janssen respectfully requests that
`
`the Board admit S. Isaac Olson pro hac vice in this proceeding.
`
`Date: August 19, 2016
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`/Dianne B. Elderkin/
`Dianne B. Elderkin
`Registration No. 28,598
`Counsel for Patent Owner
`
`
`
`
`
`
`
`5
`
`
`
`IPR2016-00286
`Patent No. 8,822,438 B2
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Janssen
`
`Oncology, Inc.’s Motion for Pro Hac Vice Admission of S. Isaac Olson was served
`
`on counsel of record on August 19, 2016 by filing this document through the End-
`
`to-End System, as well as delivering a copy via electronic mail to counsel of record
`
`for the Petitioner at the following addresses:
`
`
`
`William Hare
`Gabriela Materassi
`McNeeley Hare & War LLP
`bill@miplaw.com
`materassi@miplaw.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`By: /Dianne B. Elderkin/
`Dianne B. Elderkin
`Registration No. 28,598
`Counsel for Patent Owner
`
`
`
`Date: August 19, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`6
`
`